WO2026053150 - PHARMACEUTICAL COMPOSITIONS FOR ENHANCED SOLUBILITY AND BIOAVAILABILITY OF HYDROPHOBIC DRUGS
National phase entry is expected:
Publication Number
WO/2026/053150
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058927
International Filing Date
04.09.2025
Title **
[English]
PHARMACEUTICAL COMPOSITIONS FOR ENHANCED SOLUBILITY AND BIOAVAILABILITY OF HYDROPHOBIC DRUGS
[French]
COMPOSITIONS PHARMACEUTIQUES POUR UNE SOLUBILITÉ ET UNE BIODISPONIBILITÉ AMÉLIORÉES DE MÉDICAMENTS HYDROPHOBES
Applicants **
INTREPID LABS INC.
Inventors
BANNIGAN, Pauric
HICKMAN, Riley J.
WANG, Xuehan
ALLEN, Christine J.
Priority Data
63/691,617
06.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3565 | |
| EPO | Filing, Examination, Granting | 40510 | |
| Japan | Filing, Examination, Granting | 3482 | |
| South Korea | Filing, Examination, Granting | 4996 | |
| USA | Filing, Examination, Granting | 12940 |
Total:
65,493
Contact Us
Abstract[English]
The present disclosure provides pharmaceutical compositions, e.g., drug-containing nanocomposites, nanosuspensions thereof, and lyophilized powders thereof, that increase the apparent water solubility of hydrophobic active pharmaceutical ingredients and provide improved oral bioavailability and pharmacokinetic properties.[French]
La présente divulgation concerne des compositions pharmaceutiques, par exemple, des nanocomposites contenant un médicament, des nanosuspensions de celles-ci, et des poudres lyophilisées de celles-ci, qui augmentent la solubilité apparente dans l'eau d'ingrédients pharmaceutiques actifs hydrophobes et confèrent une biodisponibilité par voie orale et des propriétés pharmacocinétiques améliorées.